[First choice drug for treatment of osteoporosis and the strategic points for choice of drugs].
Soen
Satoshi
S
Department of Orthopaedic Surgery and Rheumatology, Nara Hospital, Kinki University School of Medicine.
D015519:Bone Density; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D002118:Calcium / Q000627:therapeutic use; D002762:Cholecalciferol / Q000627:therapeutic use; D004164:Diphosphonates / Q000627:therapeutic use*; D019317:Evidence-Based Medicine; D005265:Femoral Neck Fractures / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D015201:Meta-Analysis as Topic; D010024:Osteoporosis / Q000188:drug therapy* / Q000517:prevention & control; D017410:Practice Guidelines as Topic; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use; D016103:Spinal Fractures / Q000209:etiology / Q000517:prevention & control
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D020845:Selective Estrogen Receptor Modulators; D002762:Cholecalciferol; D020849:Raloxifene Hydrochloride; D002118:Calcium